T. Rowe Price Associates
CAPR icon

T. Rowe Price Associates’s Capricor Therapeutics CAPR Stock Holding History

T. Rowe Price Associates’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
44,748
+13,753
+44% +$417K ﹤0.01% 2298
2026
Q1 		$943K Buy
30,995
+7,843
+34% +$209K ﹤0.01% 2190
2025
Q4 		$669K Buy
23,152
+2,578
+13% +$33.7K ﹤0.01% 2268
2025
Q3 		$149K Buy
20,574
+1,556
+8% +$11.5K ﹤0.01% 2851
2025
Q2 		$189K Buy
19,018
+3,490
+22% +$36.9K ﹤0.01% 2733
2025
Q1 		$148K Buy
15,528
+1,286
+9% +$17.9K ﹤0.01% 2733
2024
Q4 		$197K Buy
+14,242
New +$250K ﹤0.01% 2688

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates's CAPR Position: Q2 2026 in Review

T. Rowe Price Associates increased its Capricor Therapeutics (CAPR) stake by 44% in Q2 2026, buying an estimated $417K and bringing the position to 44,748 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2298.

T. Rowe Price Associates first reported a position in CAPR in Q4 2024 and has held it in 7 quarters since. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • T. Rowe Price Associates held 44,748 shares of Capricor Therapeutics worth $1.08M as of Q2 2026.
  • T. Rowe Price Associates bought 13,753 Capricor Therapeutics shares in Q2 2026, an estimated $417K.
  • Capricor Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2298 holding.
  • T. Rowe Price Associates first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.